Elnaggar Yosra S R, El-Massik Magda A, Abdallah Ossama Y
Department of Pharmaceutics, Faculty of Pharmacy, University of Alexandria, Alexandria, Egypt. yosra
Int J Pharm. 2009 Oct 1;380(1-2):133-41. doi: 10.1016/j.ijpharm.2009.07.015. Epub 2009 Jul 25.
Tamoxifen citrate is an antiestrogen for peroral breast cancer treatment. The drug delivery encounters problems of poor water solubility and vulnerability to enzymatic degradation in both intestine and liver. In the current study, tamoxifen citrate self-nanoemulsifying drug delivery systems (SNEDDS) were prepared in an attempt to circumvent such obstacles. Preliminary screening was carried out to select proper ingredient combinations. All surfactants screened were recognized for their bioactive aspects. Ternary phase diagrams were then constructed and an optimum system was designated. Three tamoxifen SNEDDS were then compared for optimization. The systems were assessed for robustness to dilution, globule size, cloud point, surface morphology and drug release. An optimum system composed of tamoxifen citrate (1.6%), Maisine 35-1 (16.4%), Caproyl 90 (32.8%), Cremophor RH40 (32.8%) and propylene glycol (16.4%) was selected. The system was robust to different dilution volumes and types. It possessed a mean globule size of 150 nm and a cloud point of 80 degrees C. Transmission electron microscopy demonstrated spherical particle morphology. The drug release from the selected formulation was significantly higher than other SNEDDS and drug suspension, as well. Realizing drug incorporation into an optimized nano-sized SNEDD system that encompasses a bioactive surfactant, our results proposed that the prepared system could be promising to improve oral efficacy of the tamoxifen citrate.
枸橼酸他莫昔芬是一种用于口服治疗乳腺癌的抗雌激素药物。该药物递送存在水溶性差以及在肠道和肝脏中易被酶降解的问题。在本研究中,制备了枸橼酸他莫昔芬自纳米乳化药物递送系统(SNEDDS),试图克服这些障碍。进行了初步筛选以选择合适的成分组合。所有筛选的表面活性剂均因其生物活性方面而被认可。然后构建了三元相图并确定了最佳体系。接着比较了三种他莫昔芬SNEDDS以进行优化。对这些体系进行了稀释稳定性、球粒大小、浊点、表面形态和药物释放的评估。选择了一种由枸橼酸他莫昔芬(1.6%)、Maisine 35-1(16.4%)、己酰基90(32.8%)、聚氧乙烯蓖麻油RH40(32.8%)和丙二醇(16.4%)组成的最佳体系。该体系对不同的稀释体积和类型具有稳定性。其平均球粒大小为150 nm,浊点为80℃。透射电子显微镜显示为球形颗粒形态。所选制剂的药物释放也显著高于其他SNEDDS和药物混悬液。通过将药物掺入包含生物活性表面活性剂的优化纳米尺寸SNEDD系统中,我们的结果表明所制备的系统有望提高枸橼酸他莫昔芬的口服疗效。